+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P05016(PIM3 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The PIM3 antibody is a research tool designed to target the Proviral Integration site for Moloney murine leukemia virus 3 (PIM3) kinase, a member of the serine/threonine kinase family. PIM kinases (PIM1. PIM2. PIM3) are evolutionarily conserved regulators of cell survival, proliferation, and apoptosis, often overexpressed in cancers. PIM3. specifically, shares structural and functional similarities with PIM1 and PIM2 but exhibits distinct tissue expression patterns, with higher activity in certain solid tumors (e.g., pancreatic, liver, prostate cancers) and hematologic malignancies. Unlike many kinases, PIM3 is constitutively active and does not require phosphorylation for activation, making it a potential therapeutic target.

PIM3 antibodies are primarily used to detect PIM3 expression and localization in biological samples via techniques like Western blotting, immunohistochemistry, and flow cytometry. These antibodies help researchers investigate PIM3's role in tumor progression, drug resistance, and interactions with signaling pathways (e.g., PI3K/AKT/mTOR, JAK/STAT). Elevated PIM3 levels are linked to poor prognosis in some cancers, driving interest in its inhibition. Additionally, PIM3 inhibitors and antibodies are explored for combinatorial therapies, as PIM3 knockdown may sensitize cancer cells to chemotherapy or targeted agents. Validating PIM3 antibody specificity remains critical due to high homology among PIM isoforms. Overall, PIM3 antibodies serve as essential tools for understanding its oncogenic mechanisms and advancing biomarker-driven cancer therapies.